Read by QxMD icon Read

Cardiac allograft vasculopathy

Daliang Yan, Xiaojuan Liu, Lu Hua, Kunpeng Wu, Xilin Sha, Jianhua Zhao, Chen Yang, Chao Zhang, Jiahai Shi, Xiang Wu
Cardiac allograft vasculopathy (CAV) was the leading cause of late death in heart transplantation recipients. Matrix metalloproteinase-14 (MMP-14), as a member of the MMPs family, has been reported to play a vital role in coronary vascular lesions of allotransplanted hearts. However, concrete mechanism is still unclear. Herein, we showed that the expression of MMP-14 was different between isografts and allografts. Interestingly, we found MMP-14 could interact with CD44 in allografts. Cluster of differentiation 44 (CD44), as a cell adhesion receptor and is involved in cell migration, caused our interest in MMP-14/CD44 complex in allografts...
September 25, 2016: Pathology, Research and Practice
Marco Masetti, Luciano Potena
No abstract text is available yet for this article.
August 30, 2016: Journal of Heart and Lung Transplantation
Omar Wever-Pinzon, Leah B Edwards, David O Taylor, Abdallah G Kfoury, Stavros G Drakos, Craig H Selzman, James C Fang, Lars H Lund, Josef Stehlik
BACKGROUND: Survival beyond 1 year after heart transplantation has remained without significant improvement for the last 2 decades. A more individualized approach to post-transplant care could result in a reduction of long-term mortality. Although recipient age has been associated with an increased incidence of certain post-transplant morbidities, its effect on cause-specific mortality has not been established. METHODS: We analyzed overall and cause-specific mortality of heart transplant recipients registered in the International Society for Heart and Lung Transplantation Registry between 1995 and 2011...
August 20, 2016: Journal of Heart and Lung Transplantation
Joshua L Chan, Jon A Kobashigawa, Heidi J Reich, Danny Ramzy, Maria M Thottam, Zhe Yu, Tamar L Aintablian, Frank Liou, Jignesh K Patel, Michelle M Kittleson, Lawrence S Czer, Alfredo Trento, Fardad Esmailian
BACKGROUND: The Organ Care System, an ex-vivo heart perfusion platform, represents an alternative to the current standard of cold organ storage that sustains the donor heart in a near-physiologic state. It is unknown whether using the Organ Care System influences 2-year outcomes after heart transplantation. We reviewed our institutional experience to compare 2-year outcomes for patients randomized to the Organ Care System or standard cold storage. METHODS: Between 2011 and 2013, heart transplant candidates from a single tertiary-care medical center enrolled within the PROCEED II trial were randomized to either standard cold storage or the Organ Care System...
August 20, 2016: Journal of Heart and Lung Transplantation
Patrizia Pedrotti, Claudia Vittori, Rita Facchetti, Stefano Pedretti, Santo Dellegrottaglie, Angela Milazzo, Maria Frigerio, Manlio Cipriani, Cristina Giannattasio, Alberto Roghi, Ornella Rimoldi
AIMS: The aim of the present study was to assess the association of the presence and amount of late gadolinium enhancement (LGE) at cardiac magnetic resonance (CMR) with cardiovascular adverse events in patients with orthotopic heart transplantation (HTx). METHODS AND RESULTS: We enrolled 48 patients (mean age, 54.7 ± 14.6 years; 37 men) at various stages after HTx. All patients underwent standard CMR at 1.5 T, to characterize both cardiac anatomy and LGE. Late gadolinium enhancement was detected in 26 patients (54%)...
September 13, 2016: European Heart Journal Cardiovascular Imaging
Xiaojuan Liu, Daliang Yan, Yangcheng Li, Xilin Sha, Kunpeng Wu, Jianhua Zhao, Chen Yang, Chao Zhang, Jiahai Shi, Xiang Wu
BACKGROUND: Cardiac allograft vasculopathy (CAV) decreases the long-term survival of heart transplantation recipients. Vascular smooth muscle cell (VSMC) apoptosis is an important pathological feature of CAV. Erythroblast transformation-specific 2 (Ets-2), as a transcription factor, participates in cell apoptosis and plays an important role in organ transplantation. METHODS: Hearts from Wistar-Furth (WF:RT1u) rats were heterotopically transplanted into Lewis (Lew:RT1(l)) rats without immunosuppression...
August 2016: Journal of Thoracic Disease
Eduardo Barge-Caballero, Cayetana Barbeito-Caamaño, Gonzalo Barge-Caballero, David Couto-Mallón, María J Paniagua-Martín, Raquel Marzoa-Rivas, Miguel Solla-Buceta, Francisco Estévez-Cid, José M Herrera-Noreña, José J Cuenca-Castillo, José M Vázquez-Rodríguez, María G Crespo-Leiro
INTRODUCTION AND OBJECTIVES: To assess the potential association between recipient Toxoplasma gondii serostatus and outcomes after heart transplant (HT). METHODS: We conducted a retrospective single-center study of 657 HT recipients from 1991 to 2015. Survival and the incidence of adverse clinical events of T. gondii-seropositive (n = 481) vs T. gondii-seronegative (n = 176) recipients were compared by means of 2 different multivariable Cox regression models...
August 30, 2016: Revista Española de Cardiología
G Galli, K Caliskan, A H M M Balk, R van Domburg, O Birim, J Salerno-Uriarte, O C Manintveld, A A Constantinescu
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of graft failure after heart transplantation. However, the impact of CAV may vary according to the definition and the regional differences in transplantation settings. OBJECTIVES: We sought to assess CAV prevalence, predictors and prognosis in Dutch heart transplant recipients based on coronary angiography, following the 2010 standard nomenclature of the International Society for Heart and Lung Transplantation...
September 1, 2016: Netherlands Heart Journal
Ali Javaheri, Maria Molina, Payman Zamani, Amrith Rodrigues, Eric Novak, Susan Chambers, Patricia Stutman, Wilhelmina Maslanek, Mary Williams, Scott M Lilly, Peter Heeger, Mohamed H Sayegh, Anil Chandraker, David M Briscoe, Kevin P Daly, Randall Starling, David Ikle, Jason Christie, J Eduardo Rame, Lee R Goldberg, Jeffrey Billheimer, Daniel J Rader
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major cause of mortality after cardiac transplantation. High-density lipoprotein (HDL) cholesterol efflux capacity (CEC) is inversely associated with coronary artery disease. In 2 independent studies, we tested the hypothesis that reduced CEC is associated with mortality and disease progression in CAV. METHODS: We tested the relationship between CEC and survival in a cohort of patients with CAV (n = 35). To determine whether reduced CEC is associated with CAV progression, we utilized samples from the Clinical Trials in Organ Transplantation 05 (CTOT05) study to determine the association between CEC and CAV progression and status at 1 year (n = 81), as assessed by average change in maximal intimal thickness (MIT) on intravascular ultrasound...
July 15, 2016: Journal of Heart and Lung Transplantation
B Szyguła-Jurkiewicz, M Zakliczyński, W Szczurek, M Skrzypek, M Gąsior, M Zembala
BACKGROUND: Cardiac allograft vasculopathy (CAV) still remains to be one of the most important limiting factors for heart transplant recipients' long-term survival. The aim of our study was to identify the perioperative risk factors impacting the occurrence of CAV during the long-term follow-up. METHODS: We retrospectively analysed the data from 198 consecutive adult patients, who underwent heart transplantation between 2007 and 2012, in whom at least one routine coronarography (CAG) was performed...
June 2016: Transplantation Proceedings
Nowell M Fine, Sudhir S Kushwaha
The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus are increasingly utilized in cardiothoracic transplantation. Several recent clinical trials have demonstrated their efficacy in combination with reduced cyclosporine dosing in de novo heart transplant recipients, in particular with everolimus. A number of other studies have demonstrated their efficacy for improving renal function and reducing calcineurin inhibitor use, attenuating cardiac allograft vasculopathy progression and reducing cytomegalovirus infections in maintenance heart transplant populations...
August 5, 2016: Transplantation
Takuya Watanabe, Osamu Seguchi, Masanobu Yanase, Tomoyuki Fujita, Yoshihiro Murata, Takuma Sato, Haruki Sunami, Seiko Nakajima, Yu Kataoka, Kunihiro Nishimura, Eriko Hisamatsu, Kensuke Kuroda, Norihiro Okada, Yumiko Hori, Kyoichi Wada, Hiroki Hata, Hatsue Ishibashi-Ueda, Yoshihiro Miyamoto, Norihide Fukushima, Junjiro Kobayashi, Takeshi Nakatani
BACKGROUND: The influence of preexisting donor-transmitted atherosclerosis (DA) on cardiac allograft vasculopathy (CAV) development remains unclear. METHODS: We performed 3-dimensional intravascular ultrasound (3D-IVUS) analysis in 42 heart transplant (HTx) recipients at 2.1±0.9 months (baseline) and 12.2±0.4 months post-HTx, as well as consecutive 3D-IVUS analyses up to 3 years post-HTx in 35 of the 42 recipients. DA was defined as a maximal intimal thickness (MIT) ≥0...
July 28, 2016: Transplantation
Kyoung-Ha Park, Tao Sun, Zhi Liu, Shi-Wei Yang, Ryan J Lennon, Lilach O Lerman, Sudhir S Kushwaha, Amir Lerman
BACKGROUND: Cardiac allograft vasculopathy (CAV) is an accelerated form of coronary artery disease, and optical coherence tomography (OCT) provides detailed microstructural information. The current study was designed to test the hypothesis that markers of plaque vulnerability derived from OCT could predict CAV progression after heart transplantation (HTx). METHODS: In 34 consecutive patients (median 3.1 years from HTx), intravascular ultrasound (IVUS) and OCT were performed in the left anterior descending artery (LAD) during routine annual coronary angiography...
June 7, 2016: Journal of Heart and Lung Transplantation
Ahmed Tawakol, Jean-Claude Tardif
No abstract text is available yet for this article.
July 26, 2016: Journal of the American College of Cardiology
Kozo Okada, William F Fearon, Helen Luikart, Hideki Kitahara, Kyuhachi Otagiri, Shigemitsu Tanaka, Takumi Kimura, Paul G Yock, Peter J Fitzgerald, Alan C Yeung, Hannah A Valantine, Kiran K Khush, Yasuhiro Honda
BACKGROUND: Although cardiac allograft vasculopathy (CAV) is typically characterized by diffuse coronary intimal thickening with pathological vessel remodeling, plaque instability may also play an important role in CAV. Previous studies of native coronary atherosclerosis have demonstrated associations between attenuated-signal plaque (ASP), plaque instability, and adverse clinical events. OBJECTIVES: This study's aim was to characterize the association between ASP and long-term mortality post-heart transplantation...
July 26, 2016: Journal of the American College of Cardiology
Barbara Stella Doumouras, Ana Carolina Alba, Farid Foroutan, Luke James Burchill, Anne I Dipchand, Heather Joan Ross
BACKGROUND: Studies assessing mortality and morbidity in adult transplant recipients with congenital heart disease (CHD) are limited. We conducted a systematic review and meta-analysis comparing post-transplant outcomes in these 2 populations. METHODS: After conducting an electronic database search, we selected studies evaluating mortality, cause-specific mortality, and risk of reoperation and dialysis in adult CHD vs non-CHD patients. We used random-effects models for the meta-analysis...
June 7, 2016: Journal of Heart and Lung Transplantation
Michael Dandel, Roland Hetzer
INTRODUCTION: Close surveillance for acute rejection (AR) and cardiac allograft vasculopathy (CAV) is essential for graft and patient survival. Because CAV can arise and progress without symptoms and subclinical ARs can facilitate CAV development, standard surveillance of AR and CAV is based on routine endomyocardial biopsies (EMBs) and coronary angiographies (CA) performed at predefined time intervals. These invasive screening tests can be quite distressing for patients, yet they cannot identify all sub-clinical ARs or coronary stenoses prior to a clinical event...
October 2016: Expert Review of Cardiovascular Therapy
M M H Huibers, A J Gareau, J M T Beerthuijzen, E Siera-de Koning, J van Kuik, E G Kamburova, A Vink, N de Jonge, T D G Lee, H G Otten, R A de Weger
Cardiac allograft vasculopathy (CAV) is a transplant pathology limiting graft survival after heart transplantation. CAV arteries are surrounded by ectopic lymphoid structures (ELS) containing B- and plasma cells. The aim of this study was to characterize the antigenic targets of antibodies produced in ELS Coronary arteries and surrounding epicardial tissue from 56 transplant recipients were collected during autopsy. Immunofluorescence was used to identify antibody-producing plasma cells. Immunoglobulin levels in tissue lysates were measured by ELISA, and analysed for donor specific HLA antibodies by Luminex...
July 18, 2016: American Journal of Transplantation
Kevin J Clerkin, Susan W Restaino, Emmanuel Zorn, Elena R Vasilescu, Charles C Marboe, Donna M Mancini
BACKGROUND: Antibody-mediated rejection (AMR) has been associated with increased death and cardiac allograft vasculopathy (CAV). Early studies suggested that late AMR was rarely associated with graft dysfunction, whereas recent reports have demonstrated an association with increased mortality. We investigated the timing of AMR and its association with graft dysfunction, death, and CAV. METHODS: This retrospective cohort study identified all adult orthotopic heart transplant (OHT) recipients (N = 689) at Columbia University Medical Center from 2004 to 2013...
September 2016: Journal of Heart and Lung Transplantation
Andrew Kei-Yan Ng, Man Hong Jim, Gabriel Wai-Kwok Yip, Pauline Yeung Ng, Katherine Fan
No abstract text is available yet for this article.
October 1, 2016: International Journal of Cardiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"